The mental healthcare system is in desperate need of innovation.
By harnessing the enormous potential of rapid acting psychedelics and digital technology we aim to deliver psychedelic therapies to all those who need them — where and when they need them.
An atai Life Sciences company
Viridia Life Sciences is a biotech company dedicated to developing N,N-Dimethyltryptamine in conjunction with digital therapeutics to deliver efficient, scalable treatments to patients on their own terms.
This pragmatic approach to simplifying DMT administration and the in-clinic treatment paradigm will help people access not only the neurogenic benefits of DMT, but also the personal insights that can accompany psychedelic-assisted psychotherapy… The impact for patients and their families may be transformative.- Glenn Short
, CEO, Viridia Life Sciences
Our Team
The Viridia Team
Dean
Carson, Ph.D.
Company Lead, Viridia Life Sciences and EmpathBio
Royal
Sirasala
Senior Director, Project Management
Glenn
Short, Ph.D.
SVP, EARLY DEVELOPMENT
Galyna
Pidpruzhnykova, Ph.D.
SENIOR DIRECTOR, INNOVATION STRATEGY
Sarah
Popham
VP, Regulatory Affairs
